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Abstract
Background: Diuretics are co-adminstered with hepatoprotectant drugs for the treatment of oedema and ascitis in 
patients suffering from hepatic cirrhosis.This work presents an accurate and simple method for the in vivo analysis 
of Dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB), a hepatoprotectant 
drug, with hydrochlorothiazide (HCT) and amiloride hydrochloride (AM) diuretics in human plasma using HPLC. 
Methodology/Principal Findings: The separation was achieved on Spheri-5 RP-8 (5µ) and Spheri-5 RP-18 (5µ) 
columns (220 × 4.6 mm i.d.) using 0.02 M disodium hydrogen phosphate, 0.12% w/v sodium laurylsulfate, 0.1% 
v/v triethylamine adjusted to pH 4 and acetonitrile in a ratio 65:35 v/v as mobile phase. The separation was carried 
out at ambient temperature with a flow rate of 1.0 mL min-1. Quantitation was achieved with UV detection at 278 
nm based on peak area with linear calibration curves at concentration ranges 0.03–30 μg mL-1 for HCT and 0.05–
30 μg mL-1 for both AM amd DDB. Conclusions: The proposed method was successfully applied to the 
determination of the investigated drugs in human plasma sample obtained from a healthy male volunteer four 
hours after single oral dose administration of the three drugs. The proposed method was validated in terms of 
linearity, accuracy, precision, limits of detection and quantitation and other aspects of analytical validation.
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1. Introduction
     Dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) has a scavenging effect 
on the active oxygen radicals[1]. DDB was shown to protect hepatocytes against injury induced by chemical toxins 
such as carbon tetrachloride and D- galactosamine. DDB significantly increased the liver detoxicating ability and 
antagonized the mutagenicity of chemical carcinogens such as aflatoxin B and benz (a) pyrene. In addition, DDB 
improved apparent liver functions as evidenced by reduction in elevated levels of glutamate pyruvate transaminase 
(GPT), bilirubin, α-fetoprotein, as well as other symptoms of chronic hepatitis. It is currently used as a 
hepatoprotective agent[2]. DDB is a non-official drug. Few methods have been reported concerning the analysis of 
DDB. In pharmaceutical preparations, DDB has been determined using HPLC[3]. 
    Diuretics (such as amiloride hydrochloride, hydrochlorothiazide and triamterene) may be given in combination 
with DDB for the treatment of œdema and ascitis associated with hepatic cirrhosis.
       DDB has been determined as single component in plasma by several HPLC   methods[4-6]. Furthermore, 
several HPLC methods have been reported for the determination of hydrochlorothiazide[7, 8] and amiloride 
hydrochloride[9] in biological fluids.
    Diuretics (such as amiloride hydrochloride, hydrochlorothiazide and triamterene) may be given in combination 
with DDB for the treatment of œdema and ascitis associated with hepatic cirrhosis.
     The present work was directed towards the development of suitable HPLC method for the analysis of the 
hepatoprotectant drug (DDB) in combination with some diuretics (amiloride hydrochloride and 
hydrochlorothiazide) as co-administered drugs in human plasma of patients suffering from hepatic cirrhosis. 
Screening of the literature reveals that there is no reported method for the determination of DDB in such 
combinations. This work presents a rapid, specific, reliable and selective analytical method based on reversed 
phase high performance liquid chromatography with UV detection for the quantitative determination of DDB in a 
ternary mixture with hydrochlorothiazide (HCT) and amiloride hydrochloride (AM) in spiked human plasma. 
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Moreover, the method has been applied to calculate the amount of DDB, hydrochlorothiazide (HCT) and amiloride 
hydrochloride (AM) in human plasma sample obtained from a healthy male volunteer four hours after single oral 
dose administration of the three drugs.
2. Experimental
2.1. Materials and reagents
     DDB was kindly supplied by EVA pharmaceuticals, Cairo, Egypt. HCT and AM were obtained from Pharco 
pharmaceuticals, Alexandria, Egypt. All reagents used were of analytical grade. Acetonitrile (HPLC grade, 
Labscan Ltd., Dublin, Ireland) was used. The water for LC was double glass distilled. Phosphate buffer solutions
(0.05 M) of different pH values were tried. 
2.2. Apparatus
     The HPLC system comprised of Perkin-Elmer Series 200 (Pump, UV/Visible detector, Autosampler and 
Vacuum Degasser) with a Perkin-Elmer Chromatography interface Series 600 connected to a computer loaded 
with TotalChrom Workstation Perkin-Elmer Chromatography software and the computer is connected to a 
Hewlett-Packard LaserJet 1100 printer. Chromatographic separation was accomplished on Spheri-5 RP-8 (5µ) and 
Spheri-5 RP-18 (5µ) columns (220 × 4.6 mm i.d., Perkin-Elmer BrownLee columns). Centrifugation was 
performed using Sigma laboratory centrifuge 3K-30, Germany.
2.3. Chromatographic conditions
     Separation of DDB, HCT and AM was performed  using mobile phase consisting of 0.02 M disodium hydrogen 
phosphate, 0.12% w/v (0.12 gm per total 100 mL of mobile phase) sodium laurylsulfate, 0.1% v/v (0.1ml per total 
100ml of mobile phase) triethylamine adjusted to pH 4 (with 0.2M orthophosphoric acid) and acetonitrile in a ratio 
65:35 v/v .The mobile phase was filtered and degassed by passing through a 0.45 µm pore size membrane filter 
(Millipore, Milford, MA, USA) prior to use. The samples were also filtered using 0.45-mm disposable filters. The 
flow rate was 1.5 mL min-1 and the injection volume was 50 µL. All determinations were performed at ambient 
temperature with a detection wavelength of 278 nm.
2.4. Standard Solutions and Calibration Graphs
    Stock   solutions of   both DDB   and   HCT 100 µg mL-1 in acetonitrile and AM (100 µg mL-1) in water were 
prepared. The frozen plasma was thawn to be used at room temperature.  Separate aliquots of 2 mL plasma were 
transferred into a set of centrifuge tubes. The plasma sample in each tube was spiked with suitable amounts of 
standard HCT, AM or DDB solutions to obtain final concentrations within the ranges stated in table 2. Protein 
precipitation was performed by adding 2 mL acetonitrile to each sample followed by centrifugation for 15 minutes 
at 4000 g. The collected centrifugate of each sample was evaporated under nitrogen at room temperature then the 
residue was re-dissolved in 200 μL mobile phase. These final solutions were assayed under the chromatographic 
conditions mentioned above. The peak area of each concentration was plotted against the corresponding 
concentration to obtain the calibration graph for each compound.
2.5. Analysis of human plasma samples
2.5.1. Spiked human plasma
     Separate aliquots of 2 ml plasma were transferred into a set of centrifuge tubes. The plasma sample in each tube 
was spiked with suitable amount of standard HCT, AM and DDB solutions as presented in table 4 and the 
procedure was completed as mentioned under construction of calibration graphs.
2.5.2. Human plasma samples
     Human plasma sample was obtained from healthy male donor 4 hrs following a single oral dose of 10 pillules 
of DDB® (equivalent to 15 mg DDB) and one Moduretic® tablet (containing 5 mg AM and 50 mg HCT). Two ml 
aliquot of the sample was transferred into a centrifugal tube, 2 ml acetonitrile were added for protein precipitation 
and the procedure was completed as mentioned under construction of calibration graphs.
3. Results and discussion
     The absorption spectrum of DDB in methanol exhibited single maxima at 278 nm while that of HCT in 
methanol exhibited three maxima at 226, 273 and 317 nm. The absorption spectrum of AM in water shows 2 
maxima at 285 and 363 nm.  Detection at 278 nm provided greater sensitivity for analysis of the three drugs.
     The previously described experimental conditions allowed the simultaneous determination of HCT, AM and 
DDB with retention times of 1.81, 3.88 and 9.65 min., respectively (Fig. 1). The calculated chromatographic 
characteristics are listed in table 1. The three compounds are well resolved (good resolution and selectivity values) 
with reasonable run time (suitable capacity factors). In addition, the high column efficiency was indicated from the 
large number of theoretical plates.
3.1. Optimization of chromatographic conditions
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     Different mobile phases were used in order to achieve the best separation and resolution of the eluted peaks. 
The effect of acetonitrile content, concentration of sodium lauryl sulfate (SLS), concentration of triethylamine 
(TEA) as well as the effect of pH of the mobile phase on the capacity factor (K') values and number of theoretical 
plates (N) were studied. The best resolution could be achieved upon using a mobile phase consisting of 0.02M 
disodium hydrogen phosphate, 0.12% w/v SLS, 0.1% v/v TEA adjusted to pH 4 and acetonitrile in a ratio of 65 : 
35 v/v.
3.1.1. Effect of acetonitrile content in the mobile phase
     The mixture of standards was injected with mobile phases containing different proportions of acetonitrile. 
Figure 2 shows the retention times obtained for the three compounds as a function of acetonitrile content in the 
mobile phase. 35% acetonitrile was chosen to provide optimum separation with the most symmetric and well 
defined peaks. At lower acetonitrile concentrations, separation occurred but with excess tailing and increased 
retention times for DDB. Increasing acetonitrile concentrations led to overlap of HCT peak with the solvent front 
due to the decrease in the retention time.
3.1.2. Effect of sodium lauryl sulfate (SLS) concentration
      SLS was essential to improve the sharpness and symmetry of HCT and AM peaks. Figure 3 shows the effect of 
SLS concentrations on the retention time of the two drugs. It causes a slight increase in the retention times of HCT 
and AM while nearly no change in the retention time of DDB. A concentration of 0.12 % w/v SLS in the mobile 
phase was found optimum and produced maximum sharpness and symmetry of HCT peak.
3.1.3. Effect of triethylamine (TEA) concentration
      TEA was essential to improve the sharpness and symmetry of HCT and AM peaks. As TEA concentration 
increases, the retention time of the three drugs was slightly decreased (Fig. 4). An intermediate concentration of 
0.1% v/v was found to be optimum to obtain maximum sharpness and symmetry of the peaks.
3.1.4. Effect of pH
      The influence of pH of the aqueous phase was studied by using 0.02M solutions of disodium hydrogen 
phosphate containing 0.12% w/v SLS and 0.1% v/v TEA at various pH values between 3.0 - 7.0 (adjusted with 
orthophosphoric acid or sodium hydroxide).
These solutions were used with 35% acetonitrile as the mobile phase for a mixture of the three drugs. As the pH 
increased, the retention times of both HCT and DDB were slightly decreased while that of AM was slightly 
increased (Fig. 5). pH 4 was chosen as intermediate pH providing maximum separation of HCT peak from the
solvent front.
3.2. Assay of human plasma samples
     Peak plasma concentration of HCT is (0.18 - 0.43 µg mL-1) with a mean of 0.26 µg.ml-1 attained in 2-4 hrs 
following oral dose of 50 mg given to 8 subjects .A steady state plasma concentration of 0.05 - 0.16 µg mL-1
(mean of 0.1) attained after daily oral doses of 75 mg to 8 subjects[10]. For AM, peak plasma concentrations of 
about 0.05 µg mL-1 were attained in 4 hrs after a single oral dose of 20 mg to 6 subjects[10]. Meanwhile, plasma 
concentration profile of DDB was found to reach its peak (25.2 - 47.4 ng mL-1) at 2.21 ± 1.16 hr[11] following an 
oral administration to adult volunteers.
     The prime focus of the study was to develop, validate and apply an analytical HPLC method intended to 
measure the concentrations of the three co-administered drugs at the therapeutic plasma concentration range after 
single oral dose administration of the three drugs.
     The proposed method was applied for the determination of HCT, AM and DDB in spiked human plasma. In 
order to remove matrix interference that might overlap with the compounds of interest, samples were subjected to 
a clean-up procedure. In this respect, acetonitrile was used for protein precipitation.
     Furthermore, plasma sample obtained from a healthy male volunteer 4 hrs following a single oral dose of 10 
pillules of DDB® (equivalent to 15 mg DDB) and one Moduretic® tablet (containing 5 mg AM and 50 mg HCT) 
was analyzed using the proposed HPLC method. HCT, AM and DDB concentrations calculated in the plasma of 
the donor, were found to be 123, 21.4 and 37.3 ng mL-1, respectively.  The obtained plasma concentrations were in 
good agreement with the reported values for HCT and DDB while the plasma concentration for AM was slightly 
higher than that mentioned in the literature. This may be attributed to individual variations in the nature, rate of 
absorption and metabolic rate.      
4. Validation
4.1. Linearity
     The quantitative determination of HCT, AM and DDB was carried out based on the linear dependence of the 
peak area on the concentration (μg mL-1). Linearity was evaluated by determining five standard working solutions 
of each drug within the linearity ranges stated in table 2 in triplicates.  Peak area and concentration was subjected 
to least squares linear regression analysis to calculate the calibration equation and correlation coefficients. The 
regression data showed a good linear relationship over the working concentration ranges of the three drugs. The 
linearity of calibration graphs was validated by a high value of correlation coefficient, small values of intercepts. 
An important statistic for indicating the random error in the estimated values of y is the standard error of the 
estimate, or the standard deviation about regression, or the standard deviation of the residuals, Sy/x. The smaller the 
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standard error of the estimate, the closer will be the points to the straight line. Also, the importance of Sy/x
originates from being used to calculate Sa and Sb, the standard deviation of the intercept (a) and the slope (b). In 
addition, the standard deviation of slope % values (Sb %) were less then 2%. For more confirmation, the Student’s 
t-test was performed to determine whether the experimental intercept (a) of the above-mentioned regression lines 
was not significantly different from the null hypothesis. The calculated values of t (a/Sa) do not exceed the 95% 
criterion of t = 2.31 for 5 samples. So the intercepts are not significantly different from zero in the proposed 
methods. Thus, the hypothesis that (a) is of negligible value is confirmed. Linearity results are depicted in table 2 
for the proposed HPLC method.
4.2. Detection and quantitation limits
     Limit of detection (LOD) was defined as the concentration which had a signal to noise ratio of 3:1. For the limit 
of quantitation LOQ, the signal to noise ratio considered was 10:1[12]. The LOD and LOQ values for the drug were 
calculated and presented in table 2.
4.3. Precision and accuracy
     In order to assess the precision, as percentage relative standard deviation (RSD %) and the accuracy, as 
percentage relative error (Er %) of the proposed HPLC method, three replicate determinations were carried out on 
HCT/AM/DDB synthetic mixtures of different proportions. The data shown in table 3 indicate good precision and 
accuracy of the proposed method.
   The within-day precision and accuracy for the determination of the three drugs in plasma were conducted using 
three replicate determinations for each concentration of the three drugs. The between-day precision and accuracy 
were similarly evaluated on several days over two weeks and no more than one assay per day for each 
concentration. The data presented in table 4 indicate that the within-day and between-day coefficients of variation 
(RSD %) and the percentage relative error (Er %) for HCT, AM and DDB are generally lower than 3%.
4.4. Selectivity
    The selectivity of the method was assessed by carrying out the chromatographic procedure on blank plasma 
samples (after being cleaned-up) and no interfering peaks were detected at the retention times of the analytes, it 
was then concluded that no endogenous substances from the plasma interfered with the assay.
     The stability of the column was not affected by the injection of plasma samples (after deproteinization). The 
resolution as well as the retention times of the drugs peaks remained constant over two weeks of work.
Table 1: Chromatographic characteristics of HCT, AM and DDB.
Compound
Retention
Time, min.
Number of
theoretical
Plates, N
Capacity
Factor, K'
Selectivity,
α
Resolution,
R
HCT
AM
DDB
1.81
3.88
9.65
2318
1594
6031
0.65
2.53
7.77
2.14
2.49
6.24
9.66
Both the selectivity and resolution were calculated for each two successive peaks.
Table 2: Regression and statistical parameters for the determination of a mixture of HCT, AM and DDB by 
the proposed HPLC method.
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Parameter HCT AM DDB
Linearity range
(μg.ml-1) 0.03-30 0.05-30 0.05-30
Regression equation
Intercept (a)
Slope (b)
Correlation coefficient (r)
-2.97 × 104
9.86 × 104
0.9998
3.78 × 104
1.57 × 105
0.9999
4.74 × 103
9.93 × 104
0.9999
Sa 1.02 × 10
5 1.03 × 105 3.03 × 103
Sb 1.22 × 10
3 1.27 × 103 67.55
Sy/x 1.54 × 10
5 1.75 × 105 5.93 × 103
LOD (ng.ml-1) 8 14 15
LOQ (ng.ml-1) 27 45 48
Sa : Standard deviation of the intercept, Sb : Standard deviation of the slope, Sy/x : Standard deviation of residuals, 
LOD : Limit of detection, LOQ : Limit of quantitation.
Table 3: Evaluation of the precision and accuracy for the determination of HCT, AM and DDB in synthetic 
mixtures by the proposed HPLC method.
Nominal value
(μg.ml-1)
Mean % recovery ± SD RSD (%) Er (%)
HCT AM DDB HCT AM DDB HCT AM DDB HCT AM DDB
0.03 0.1 0.1
100.25 
±
1.262
100.06 
±
1.517
100.20 
± 
1.214
1.259 1.516 1.212 0.25 0.06 0.20
2 0.5 0.45
100.08 
± 
0.233
100.08
±
0.226
99.66 
±
0.600
0.233 0.226 0.602 0.08 0.08 -0.34
1 8 2
99.94 
± 
0.596
99.05
±
0.548
99.84 
±
0.647
0.596 0.553 0.648 -0.06 -0.95 -0.16
8 2 8
100.00
±
0.348
99.47
±
0.458
99.92
±
0.492
0.348 0.460 0.492 0.00 -0.53 -0.08
15 10 10
100.19
±
0.490
99.19
±
0.409
100.40 
±
0.901
0.489 0.412 0.897 0.19 -0.81 0.40
Mean ± standard deviation of three determinations. 
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Table 4: Assay results for the determination of HCT, AM and DDB spiked to human plasma by the proposed HPLC method.
Spiked conc.
(µg.ml-1)
Measured conc.
(µg.ml-1)
Mean % recovery ± SD RSD (%) Er (%)
HCT AM DDB HCT AM DDB HCT AM DDB HCT AM DDB HCT AM DDB
(a) Within-day precision and accuracy
0.1 0.015 0.03 1 0.15 0.3
97.90 
± 
1.809
98.34 ± 
1.532
97.31 ± 
1.691
1.848 1.558 1.670 -2.10 -3.66 -2.69
0.2 0.05 0.045 2 0.5 0.45
98.05 
± 
1.431
101.04 
±1.325
97.91 ± 
1.024
1.416 1.311 1.025 -1.95 -2.96 -2.09
0.5 0.5 0.1 5 5 1
98.11 
± 
1.595
101.38 ± 
0.678
96.24 ± 
1.353
1.593 0.669 1.363 -1.89 -1.62 -3.76
1 1 1 10 10 10
97.42 
± 
0.933
102.71 ± 
0.421
98.51 ± 
0.876
0.938 0.410 0.863 -2.58 -2.29 -1.49
2 2 3 20 20 30
98.97 
± 
0.979
99.72 ± 
1.123
97.83 ± 
0.997
0.989 1.126 0.989 -1.03 -2.28 -2.17
(b) Between-day precision and accuracy
0.1 0.015 0.03 1 0.15 0.3
96.26 
± 
2.771
101.71 ± 
1.935
97.51 ± 
3.035
2.820 1.902 2.806 -3.74
-
4.29
-2.49
0.2 0.05 0.045 2 0.5 0.45
97.34 
± 
1.855
100.39 ± 
2.126
98.71 ± 
2.133
1.867 2.118 2.139 -2.66
-
1.61
-1.29
0.5 0.5 0.1 5 5 1
97.61 
± 
2.128
101.53 ± 
1.125
98.13 ± 
1.745
2.094 1.108 1.778 -2.39
-
2.47
-1.87
1 1 1 10 10 10
98.33 
± 
1.908
99.09 ± 
0.981
96.35 ± 
1.671
1.902 0.990 1.682 -1.67
-
2.91
-3.65
2 2 3 20 20 30
98.67 
± 
1.865
98.97 ± 
1.133
96.35 ± 
2.041
1.853 1.145 2.014 -1.33
-
1.03
-3.65
Mean ± standard deviation of three determinations.
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Fig. 1. Typical chromatogram of 50 μl injection of [A] standard mixture of (1) 2 µg.ml-1 HCT, (2) 0.05 µg.ml-1 AM and (3) 0.45 µg.ml-1 DDB, [B] Plasma spiked to give the same concentration 
as in standard mixture and [C] drug-free plasma.
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Fig. 2. Variation in the retention times of HCT, AM and DDB as a function of the percentage of acetonitrile in the 
mobile phase.
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Fig. 3. Variation in the retention times of HCT, AM and DDB as a function of the concentration of a SLS (%w/v) 
in the mobile phase.
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Fig. 4. Variation in the retention times of HCT, AM and DDB as a function of the concentration of a TEA (%v/v) 
in the mobile phase.
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Fig. 5. Variation in the retention times of the HCT, AM and DDB as a function of pH of the aqueous phase.
5. Conclusion
     
     A validated HPLC method has been developed for the determination of HCT, AM and DDB co-administered 
drugs in human plasma. This chromatographic assay fulfilled all the requirements to be identified as a reliable and 
feasible method, including linearity, accuracy, precision and selectivity. Its chromatographic run time of 11 min 
allows the analysis of a large number of samples in a short period of time. In addition, there are no previously 
reported HPLC methods for the simultaneous determination of DDB in such combination making the proposed 
method of great interest to be adopted for biopharmaceutical studies of co-administered HCT, AM and DDB in 
human plasma of patients suffering from hepatic disorders associated with edema.
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